Clinical Molecular Imaging with PET Agents Other than 18F-FDG

Author(s): Lance T. Hall, Aaron F. Struck, Scott B. Perlman

Journal Name: Current Pharmaceutical Biotechnology

Volume 11 , Issue 6 , 2010

Become EABM
Become Reviewer
Call for Editor


Molecular imaging represents an extremely important advancement in patient care and numerous agents have been developed and are being studied. Hundreds of molecular imaging agents currently exist for use in multiple modalities such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, optical imaging, general nuclear medicine and positron emission tomography (PET). In PET, only a very small percentage of these agents are being used clinically in humans and more show promise for clinical use in the short-term future. The purpose of this paper is to present a brief overview of PET agents other than 18F-fluordeoxyglucose (FDG) that are either currently in clinical use in humans or in the authors opinion are felt to show great promise for clinical use in the near future.

Keywords: Molecular imaging, molecular imaging agents, positron emission tomography, PET, PET/CT

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [545 - 554]
Pages: 10
DOI: 10.2174/138920110792246537
Price: $65

Article Metrics

PDF: 11